Affordable Access

deepdyve-link
Publisher Website

Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks.

Authors
  • Sarkaria, Jann N
  • Galanis, Eva
  • Wu, Wenting
  • Dietz, Allan B
  • Kaufmann, Timothy J
  • Gustafson, Michael P
  • Brown, Paul D
  • Uhm, Joon H
  • Rao, Ravi D
  • Doyle, Laurence
  • Giannini, Caterina
  • Jaeckle, Kurt A
  • Buckner, Jan C
Type
Published Article
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Publication Date
Nov 15, 2010
Volume
16
Issue
22
Pages
5573–5580
Identifiers
DOI: 10.1158/1078-0432.CCR-10-1453
PMID: 20921209
Source
Medline
License
Unknown

Abstract

The increased infection rate observed with CCI-779 combined with chemoradiotherapy in GBM was reduced with antibiotic prophylaxis and by limiting the duration of CCI-779 therapy. The combined suppressive effects of CCI-779 and temozolomide therapy on discrete immune compartments likely contributed to the increased infectious risks observed.

Report this publication

Statistics

Seen <100 times